Latest / Flash Stock Reports (Video)
ABEO Has a $2.85M Gene Therapy Wall Street Missed
ABEO stock analysis: $2.85M gene therapy targets 194% upside — buy or sell?
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_video&utm_medium=explainer_video&utm_campaign=freja_and_friends
In this deep dive, we break down Abeona Therapeutics (ABEO) and its commercial transition with ZEVASKYN, a $2.85 million permanent wound-closure gene therapy supported by CMS NTAP reimbursement status. With gross margins projected to expand from 63% to 90% and a probability-weighted valuation target implying 194% total…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.